These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 11449771

  • 1. [Anagrelide in primary thrombocythemia].
    Knutsen H, Hysing J.
    Tidsskr Nor Laegeforen; 2001 May 10; 121(12):1478-82. PubMed ID: 11449771
    [Abstract] [Full Text] [Related]

  • 2. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G, Wróbel T, Podolak-Dawidziak M, Kuliszkiewicz-Janus M, Potoczek S, Nosol J, Kuliczkowski K.
    Pol Arch Med Wewn; 2004 Dec 10; 112(6):1445-50. PubMed ID: 15962609
    [Abstract] [Full Text] [Related]

  • 3. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun 10; 15(83):83-6. PubMed ID: 16764090
    [Abstract] [Full Text] [Related]

  • 4. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL, Marton É, Plander M, Szendrei T.
    Orv Hetil; 2016 Feb 28; 157(9):336-41. PubMed ID: 26895801
    [Abstract] [Full Text] [Related]

  • 5. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.
    Petrides PE, Beykirch MK, Trapp OM.
    Eur J Haematol; 1998 Aug 28; 61(2):71-6. PubMed ID: 9714517
    [Abstract] [Full Text] [Related]

  • 6. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J.
    Haematologica; 2004 May 28; 89(5):520-7. PubMed ID: 15136214
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of essential thrombocythemia in childhood.
    Scherer S, Ferrari R, Rister M.
    Pediatr Hematol Oncol; 2003 May 28; 20(5):361-5. PubMed ID: 12775533
    [Abstract] [Full Text] [Related]

  • 9. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL, Bertolino G, Noris P, Ascari E.
    Haematologica; 1992 May 28; 77(1):40-3. PubMed ID: 1398280
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia.
    Mills AK, Taylor KM, Wright SJ, Bunce I, Eliadis P, Brigden MC, Seeley G, Bashford J, Olsen T, Rentoul A, Kelly C.
    Aust N Z J Med; 1999 Feb 28; 29(1):29-35. PubMed ID: 10200810
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ, FOX study investigators.
    Eur J Haematol; 2014 Feb 28; 92(2):127-36. PubMed ID: 24118452
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anagrelide, a selective thrombocytopenic agent.
    Oertel MD.
    Am J Health Syst Pharm; 1998 Oct 01; 55(19):1979-86. PubMed ID: 9784784
    [Abstract] [Full Text] [Related]

  • 17. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
    Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, Cacciola E, Cacciola R, Candoni A, Crugnola M, Codeluppi K, Usala E, Specchia G, Martinelli V, Palmieri F, Pierri I, Liberati AM, Iurlo A, Grossi A, Vannucchi AM, Vianelli N, Mazzucconi MG.
    Leuk Res; 2011 Dec 01; 35(12):1557-63. PubMed ID: 21764130
    [Abstract] [Full Text] [Related]

  • 18. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
    Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R, Santoro C, Mandelli F.
    Haematologica; 2004 Nov 01; 89(11):1306-13. PubMed ID: 15531452
    [Abstract] [Full Text] [Related]

  • 19. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
    Petrides PE.
    Expert Opin Pharmacother; 2004 Aug 01; 5(8):1781-98. PubMed ID: 15264993
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.